Immune oncology central to Merck KGaA's pharma growth hopes
This article was originally published in Scrip
Merck KGaA is hoping to climb the pharma ranks in the next few years through the development of its pipeline and the overall makeover of the business. Comments by the chair of the firm's executive board, Dr Karl-Ludwig Kley, during the firm's annual financial results conference, highlight the importance of immune oncology in its healthcare business growth hopes.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.